MedTrace Logo

Thymic Function in Patients With COVID-19

NCT04716907 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2026-04-08

No results posted yet for this study

Summary

The main clinical manifestation associated with SARS-CoV-2 infection is an influenza-like illness that follows the infection of the respiratory tract. In a few percent of infected people, inflammation of the lungs leads to severe pneumonia that requires hospitalization, in intensive care units for the more severe cases. Despite intensive care, a fatal outcome occurs in 6% and 12% of women and men over 80 years of age hospitalized for severe COVID, respectively.

Factors associated with a higher risk of death in patients with SARS-CoV-2 include age and low circulating lymphocyte counts. Significant lymphopenia is indeed frequently observed in patients with severe COVID-19 and both phenotypic and functional changes in antiviral T cells have been correlated with the severity of COVID-19.

The thymus, the organ that produces T lymphocytes, undergoes progressive physiological involution with age. However, in the elderly, rare cases of thymic hyperplasia are reported in autoimmune diseases or cancers, or are observed in response to deep lymphopenia, whether or not associated with sepsis.

This cohort of patients treated for a SARS-CoV-2 infection could allow to better understand the role of the thymus in this pathology.

Conditions

  • Covid19

Interventions

GENETIC

Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region

DNA extraction from blood samples, PCR and Sequencing

BIOLOGICAL

Blood sample

Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.

DIAGNOSTIC_TEST

CT Scan

Thymus and lung imaging

BIOLOGICAL

Bronchial fibroscopy

Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs

Sponsors & Collaborators

  • CMC Ambroise Paré

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-19
Primary Completion
2022-04-02
Completion
2022-04-02

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04716907 on ClinicalTrials.gov